[On the therapy of bleeding tendency due to vitamin K deficiency and dysfunction of the liver during the first year of life. (Combined treatment with a concentrate of factors II, VII, IX and X and heparin) (author's transl)].
D001778:Blood Coagulation Disorders / Q000188:drug therapy*; D001779:Blood Coagulation Factors / Q000627:therapeutic use*; D001780:Blood Coagulation Tests; D004211:Disseminated Intravascular Coagulation / Q000188:drug therapy; D004927:Escherichia coli Infections / Q000150:complications; D005164:Factor IX / Q000627:therapeutic use; D005167:Factor VII / Q000627:therapeutic use; D005170:Factor X / Q000627:therapeutic use; D005260:Female; D005759:Gastroenteritis / Q000150:complications; D006493:Heparin / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008107:Liver Diseases / Q000188:drug therapy*; D008297:Male; D011516:Prothrombin / Q000627:therapeutic use; D018805:Sepsis / Q000150:complications; D014812:Vitamin K / Q000627:therapeutic use; D014813:Vitamin K Deficiency / Q000188:drug therapy*
D001779:Blood Coagulation Factors; D014812:Vitamin K; D005167:Factor VII; D011516:Prothrombin; D005164:Factor IX; D005170:Factor X; D006493:Heparin
Zur Therapie der Blutungsneigung bei Vitamin K-Mangel oder Leberfunktionsstörungen im Säuglingsalter. (Kombinierter Einsatz von Faktor II, VII, IX, X-Konzentrat und Heparin.